Septerna, Inc. (NASDAQ:SEPN) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Septerna, Inc. (NASDAQ:SEPN) has been assigned an average rating of “Moderate Buy” from the eight brokerages that are covering the company, MarketBeat reports. Two investment analysts have rated the stock with a sell recommendation, five have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $33.8333.

A number of research firms have recently weighed in on SEPN. Jones Trading started coverage on shares of Septerna in a research note on Tuesday, December 23rd. They set a “buy” rating and a $43.00 price target on the stock. Zacks Research lowered shares of Septerna from a “hold” rating to a “strong sell” rating in a research report on Friday, January 23rd. Wells Fargo & Company raised shares of Septerna from an “equal weight” rating to an “overweight” rating and increased their target price for the company from $18.00 to $28.00 in a report on Friday, November 14th. HC Wainwright boosted their price target on Septerna from $30.00 to $35.00 and gave the stock a “buy” rating in a research note on Tuesday, January 20th. Finally, Wall Street Zen cut Septerna from a “strong-buy” rating to a “buy” rating in a report on Saturday, January 10th.

Insiders Place Their Bets

In other news, SVP Daniel D. Long sold 3,501 shares of the firm’s stock in a transaction on Monday, November 10th. The stock was sold at an average price of $18.06, for a total value of $63,228.06. Following the completion of the transaction, the senior vice president owned 92,911 shares in the company, valued at $1,677,972.66. This trade represents a 3.63% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Company insiders own 4.30% of the company’s stock.

Hedge Funds Weigh In On Septerna

Hedge funds have recently added to or reduced their stakes in the business. Universal Beteiligungs und Servicegesellschaft mbH lifted its stake in Septerna by 116.7% in the 2nd quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 222,702 shares of the company’s stock valued at $2,354,000 after buying an additional 119,953 shares in the last quarter. China Universal Asset Management Co. Ltd. acquired a new position in shares of Septerna in the fourth quarter worth $287,000. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Septerna in the fourth quarter valued at $61,000. BNP Paribas Financial Markets boosted its stake in shares of Septerna by 88.0% during the third quarter. BNP Paribas Financial Markets now owns 4,155 shares of the company’s stock valued at $78,000 after acquiring an additional 1,945 shares during the last quarter. Finally, Russell Investments Group Ltd. acquired a new stake in shares of Septerna during the third quarter valued at $36,000.

Septerna Trading Up 7.1%

Shares of SEPN stock opened at $25.00 on Tuesday. The stock has a 50 day simple moving average of $26.82 and a 200-day simple moving average of $20.40. The company has a market cap of $1.12 billion, a price-to-earnings ratio of -16.56 and a beta of 3.85. Septerna has a 12-month low of $4.17 and a 12-month high of $30.50.

Septerna (NASDAQ:SEPN) last announced its quarterly earnings data on Monday, November 10th. The company reported ($0.09) earnings per share for the quarter, missing analysts’ consensus estimates of $0.19 by ($0.28). The business had revenue of $21.50 million for the quarter, compared to analyst estimates of $24.50 million. Septerna had a negative return on equity of 17.98% and a negative net margin of 266.77%. On average, equities analysts forecast that Septerna will post -7.11 earnings per share for the current fiscal year.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.